Table 2.

Univariate analysis according to 100 patients’ characteristics.

Characteristic	No.	3-year OS %	P(Univariate Analysis to OS)	3-year PFS %	P(Univariate Analysis to PFS)
Gender
Male	66	39.9	0.331	27.6	0.577
Female	34	50.3		28.9
Age
≤60 years	42	55.9	0.053	42.8	0.072
> 60 years	58	33.1		15.6
PS
0–1	79	48.6	0.000	27.6	0.042
2–4	21	22.9		23.8
Ann Arbor stage
I–II	2	50.0	0.774	50.0	0.807
III–IV	98	43.1		28.1
No. of extranodal sites
0–1	56	55.3	0.080	38.0	0.007
> 1	44	30.3		14.8
BM involvement
Yes	14	45.9	0.063	26.8	0.313
No	72	31.3		29.3
Liver involvement
Yes	11	13.6	0.035	18.2	0.360
No	89	47.2		29.1
Spleen involvement
Yes	43	39.1	0.539	27.3	0.928
No	57	46.6		22.0
B symptom
Yes	64	36.8	0.166	31.2	0.916
No	36	58.3		18.1
Rash/Pruritus
Yes	29	25.4	0.001	18.7	0.002
No	71	50.8		31.5
Anemia*
Yes	69	38.8	0.372	26.6	0.764
No	31	53.3		30.7
Platelet count
≥150 × 109/L	65	48.0	0.045	31.3	0.239
<150 × 109/L	35	33.8		22.8
Lymphocyte
normal	42	48.6	0.710	28.3	0.457
≤normal	58	40.2		32.5
Eosinophil
≥normal	19	39.0	0.648	26.3	0.481
normal	81	44.3		27.6
Monocyte
≥normal	53	34.2	0.219	18.4	0.021
normal	47	53.5		37.4
LDH level
≥normal	75	36.9	0.166	28.7	0.223
normal	25	58.4		30.6
β2-M level
≥4.0 m g/L	56	26.2	0.000	21.6	0.010
<4.0 m g/L	44	65.7		35.9
Serum albumin level
≥35 g/L	43	43.8	0.871	12.9	0.409
≤35 g/L	52	48.7		38.2
Serum globulin level
≥35 g/L	32	38.5	0.495	19.3	0.037
<35 g/L	63	51.1		34.6
IPI score
L	6	66.7	0.005	50.0	0.009
LI	24	68.1		33.2
HI	37	45.8		39.0
H	33	17.2		8.8
PIT score
Group 1	9	64.8	0.000	33.3	0.045
Group 2	35	55.0		37.9
Group 3	29	30.6		22.6
Group 4	13	23.1		23.1
Treatment*			0.816		0.763
Anthracycline-based regimens	64	45.1		26.4
Gemcitabine and Platinum	30	47.5		36.5
Pathological finding
EBER
Positive	42	51.7	0.529	26.7	0.376
Negative	15	58.7		50.0
CXCL13
Positive	46	37.9	0.348	26.4	0.919
Negative	18	55.9		30.5
BCL-6
Positive	59	41.7	0.730	42.9	0.778
Negative	7	57.1		22.2
CD10
Positive	54	48.7	0.427	26.2	0.937
Negative	23	37.3		32.8
PD-1
Positive	24	41.3	0.360	35.5	0.319
Negative	1	—		—